Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Identifier
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Cancer immunology immunotherapy. 71. -. 2022. 1975. 1988. -
- Event
-
Veröffentlichung
- (where)
-
Mainz
- (who)
-
Universitätsbibliothek der Johannes Gutenberg-Universität Mainz
- (when)
-
2022
- Creator
-
Salomon, Nadja
Selmi, Abderaouf
Grunwitz, Christian
Kong, Anthony
Stanganello, Eliana
Neumaier, Jennifer
Petschenka, Jutta
Diken, Mustafa
Kreiter, Sebastian
Türeci, Özlem
Sahin, Ugur
Vascotto, Fulvia
- DOI
-
10.25358/openscience-7649
- Handle
- URN
-
urn:nbn:de:101:1-2022090102234610756922
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Salomon, Nadja
- Selmi, Abderaouf
- Grunwitz, Christian
- Kong, Anthony
- Stanganello, Eliana
- Neumaier, Jennifer
- Petschenka, Jutta
- Diken, Mustafa
- Kreiter, Sebastian
- Türeci, Özlem
- Sahin, Ugur
- Vascotto, Fulvia
- Universitätsbibliothek der Johannes Gutenberg-Universität Mainz
Time of origin
- 2022
Other Objects (12)
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Preclinical investigation of DNA immunization with a rearranged human papillomavirus type 16 (HPV16) E7 oncogene
MPS1 is involved in the HPV16-E7-mediated centrosomes amplification
HPV16 mutant E6/E7 construct is protective in mouse model
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors
Modulation der Immunogenität von HPV16-, L1-E7-chimären Virus-ähnlichen Partikeln
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model
Evaluation of HPV16 E7 expression in head and neck carcinoma cell lines and clinical specimens
Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein
Association of cervical carcinogenesis risk with HPV16 E6 and E7 variants in the Taizhou area, China
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Preclinical investigation of DNA immunization with a rearranged human papillomavirus type 16 (HPV16) E7 oncogene
MPS1 is involved in the HPV16-E7-mediated centrosomes amplification
HPV16 mutant E6/E7 construct is protective in mouse model
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors
Modulation der Immunogenität von HPV16-, L1-E7-chimären Virus-ähnlichen Partikeln
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model
Evaluation of HPV16 E7 expression in head and neck carcinoma cell lines and clinical specimens
Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein
Association of cervical carcinogenesis risk with HPV16 E6 and E7 variants in the Taizhou area, China
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Preclinical investigation of DNA immunization with a rearranged human papillomavirus type 16 (HPV16) E7 oncogene
MPS1 is involved in the HPV16-E7-mediated centrosomes amplification
HPV16 mutant E6/E7 construct is protective in mouse model
Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors
Modulation der Immunogenität von HPV16-, L1-E7-chimären Virus-ähnlichen Partikeln
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model
Evaluation of HPV16 E7 expression in head and neck carcinoma cell lines and clinical specimens
Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein